My ePortfolio Register   

AACR 2014 /
Phase II trial shows dacomitinib benefits a subgroup of patients with head and neck cancer

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1931

Dr Byoung Chul Cho - Yonsei University College of Medicine, Seoul, Republic of Korea

Dr Byoung Chul Cho talks to ecancertv at the AACR conference about the results of a phase II clinical trial of investigational anticancer drug, dacomitinib.

The findings suggest that head and neck cancer patients whose cancer has no defects in a cell signalling pathway called the PI3K pathway, and no signs of excessive inflammation, may be benefited by the drug.

Read the article for more.




Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence